# Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

> **NCT05361915** · PHASE2 · SUSPENDED · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Abivertinib
- **DRUG:** Abiraterone

## Key facts

- **NCT ID:** NCT05361915
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-09
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Sorrento Therapeutics filed for chapter 11 bankruptcy.
- **Last updated:** 2024-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361915, "Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT05361915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*